CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 193 enrolled
Drug / intervention
Naproxen sodium/Caffeine (BAY2880376) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04132336
NCT04132336Phase 2Completed

A Randomized, Double-Blind, Single-Dose, Parallel, Placebo-Controlled Trial to Determine the Dose of Caffeine in a Fixed Dose Combination Tablet of Naproxen Sodium and Caffeine to Effectively Alleviate Postsurgical Dental Pain

Bayer·interventional·Posted Oct 18, 2019·Updated Sep 1, 2021

In Brief

A Phase 2 clinical trial evaluating Naproxen sodium/Caffeine (BAY2880376), Naproxen sodium (Aleve), and 2 other interventions for Pain, Postoperative. Completed, enrolled 193 participants across 1 site.

Detailed Summary

The researchers in this study wanted to find out the optimal dose of Caffeine in the combination tablet of Naproxen Sodium and Caffeine that works in patients experiencing moderate to severe pain after having wisdom teeth removed. In the US, Naproxen has been marketed since 1976, and Naproxen Sodium has been approved for over-the-counter (OTC) use since 1994 for the temporary relief of minor aches and pains. Caffeine, which is generally consumed as coffee, tea or cocoa, has been shown to enhance the effectiveness of various pain relievers, and therefore is accepted as an additive to painkillers like aspirin and acetaminophen. Patients participating in this study underwent a surgery to remove 3 or 4 wisdom teeth. If the pain severity after the surgery met the study requirement, patients would receive oral tablet(s) of Naproxen Sodium and Caffeine, or Naproxen Sodium, or Caffeine, or placebo (drug with no active ingredient). Patients could also receive additional pain medication when needed. Researchers would also learn if the patients have any medical problems during the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 18, 2019
Enrollment StartNov 12, 2019
Primary CompletionMar 2, 2020
Study CompletionMar 3, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.7 years ago

Interventions

Naproxen sodium/Caffeine (BAY2880376)drug

Tablet, oral, single dose

Naproxen sodium (Aleve)drug

Tablet, oral, single dose

Caffeinedrug

Tablet, oral, single dose

Placebodrug

Tablet, oral, single dose